Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Her is my answer from Hawk on the Royalty payment question

I hear you as well, but I can't wrap my head around an NDA being a reason for not providing general communication on the licensing issues. As long as the communication is done in a general way, plain talk with no specific or details. This in my mind should be acceptable to communicate to shareholders and the investment world in general. I don't care what the reason is it reflects poorly on the people in charge at PTSC.

All the best,

Steve

Share
New Message
Please login to post a reply